September round-up of pharma/biotech M&A activity

5 October 2016

Bayer's (BAYN: DE) $66 billion proposed buy of Monsanto (NYSE: MON) was the biggest deal of the month involving a pharma company, but Ireland-incorporated Allergan (NYSE: AGN) was the busiest in M&A activity overall.

Monsanto, a USA-based GMO giant, finally succumbed to the advances of the German pharma major after a prolonged pursuit, while Allergan has been wasting no time in strengthening its portfolio after its generics arm was bought by Israeli drugmaker Teva (NYSE: TEVA) this summer.

The Dublin-based company has added assets in opthalmology, dermatology and progams for non-alcoholic steatohepatitis (NASH) in a big-spending September.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK